AbCellera Biologics Inc. ABCL Tax receivable within other current assets
Tax receivable within other current assets at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxesReceivable.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s tax receivable within other current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s tax receivable within other current assets?
- AbCellera Biologics Inc. (ABCL) reported tax receivable within other current assets of $39.8M in Q1 2026.
- How has AbCellera Biologics Inc.'s tax receivable within other current assets changed year-over-year?
- AbCellera Biologics Inc.'s tax receivable within other current assets increased by 73.0% year-over-year, from $23M to $39.8M.
- What is the long-term trend for AbCellera Biologics Inc.'s tax receivable within other current assets?
- Over 3 years (2022 to 2025), AbCellera Biologics Inc.'s tax receivable within other current assets has grown at a -4.9% compound annual growth rate (CAGR), from $64.82M to $55.7M.